SINGAPORE, Sept. 29, 2015 /PRNewswire/ -- Biosensors International Group, Ltd. ("Biosensors" or the "Company", Bloomberg: BIG SP; Reuters: BIOS.SI; SGX: B20), a developer, manufacturer and marketer of innovative medical devices, today announced that the Company will commercialize its BMX-J drug-eluting stent (DES) system in Japan starting 1 October 2015.
"We are very pleased to commence sales of the BMX-J in Japan. Japan is the third largest single-country market in the world, after the United States and China. Our growth potential in the Japan market is very strong. The technology of the BMX-J, which incorporates a biodegradable polymer coating together with an immunosuppressive drug, is already well accepted by the cardiologists in Japan, as evidenced by the strong market share of the Nobori," commented Biosensors' CEO Mr. Jose Calle.
BMX-J is an OEM version of the Nobori DES, which consists of Biosensors' unique DES that incorporates a biodegradable polymer and the Company's proprietary drug, Biolimus A9®, which inhibits restenosis, or re-narrowing of the arteries, following stent implantation. The Company first announced the Japan regulatory approval of BMX-J in August this year.
"BMX-J will provide a valuable alternative to the DES currently available to interventional cardiologists in Japan," commented Mr. Calle. "We have already established a solid distribution channel across Japan. We will continue to expand these channels to increase coverage with a very clear objective of achieving a significant ramp up in sales going forward. I see this as an important milestone for our strategy in Japan."
About Biosensors International Group, Ltd
Biosensors International Group, Ltd. develops, manufactures and markets innovative medical devices, aiming to improve patients' lives through pioneering medical technology that pushes forward the boundaries of innovation. Founded in 1990, we were listed on the Mainboard of the Singapore Stock Exchange in 2005.
The Group currently operates through four business units ("BU"): the Cardiovascular BU, composed primarily of the BioMatrix™ & EXCEL families of drug-eluting stents and stent technologies such as BA9; the Cardiac Diagnostic BU, including Spectrum Dynamics products that offer advanced medical imaging and clinical solutions to help interventional cardiologists determine the most appropriate treatment for patients; the Peripheral Intervention BU, offering solutions for the treatment of patients with peripheral arterial disease; and the Critical Care Products BU.
The Group has operations worldwide and is headquartered in Singapore.
For more information, please visit www.biosensors.com.
Certain statements herein include forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements generally can be identified by the use of forward-looking terminology, such as "may," "will," "expect," "intend," "estimate," "anticipate," "believe," "project" or "continue" or the negative thereof or other similar words. All forward looking statements involve risks and uncertainties, including, but not limited to, customer acceptance and market share gains, competition from companies that have greater financial resources; introduction of new products into the marketplace by competitors; successful product development; dependence on significant customers; the ability to recruit and retain quality employees as Biosensors grows; and economic and political conditions globally. Actual results may differ materially from those discussed in, or implied by, the forward-looking statements. The forward-looking statements speak only as of the date of this release and Biosensors assumes no duty to update them to reflect new, changing or unanticipated events or circumstances.